脂蛋白(a)水平与冠心病患者复发事件的关联
该多中心前瞻性研究纳入7562例首次发生心血管事件且经血管造影确诊冠心病的患者,按脂蛋白(a)三分位分组随访。平均随访61.45±19.57个月,9.0%发生复发心血管事件,脂蛋白(a)与复发事件风险独立相关,且加入SMART风险评分可轻度改善预测。
要点
- 脂蛋白(a)较高三分位组无事件生存率显著低于最低三分位组。
- 脂蛋白(a)与复发心血管事件风险独立相关(HR 2.01,95%CI 1.44–2.80)。
- 脂蛋白(a)加入SMART评分可轻度改善对复发事件的预测。
核心结论
- 在真实世界已治疗的冠心病患者中,循环脂蛋白(a)浓度是复发心血管事件风险的有用预测指标。
研究设计与样本
- 多中心前瞻性研究,连续纳入7562例经血管造影确诊冠心病且经历首次心血管事件的患者。
- 入院时测定所有受试者脂蛋白(a)浓度,并按脂蛋白(a)三分位分组。
- 随访复发心血管事件,包括心血管死亡、非致死性心肌梗死和卒中。
主要发现
- 平均随访61.45±19.57个月期间,680例(9.0%)发生复发心血管事件。
- 事件组脂蛋白(a)水平显著高于非事件组(20.58 vs 14.95 mg/dL,p<0.001)。
- Kaplan-Meier分析显示,脂蛋白(a)第二三分位组(p=0.001)和第三三分位组(p<0.001)累积无事件生存率显著低于第一三分位组。
- 多因素Cox回归分析显示,脂蛋白(a)与复发心血管事件风险独立相关(HR 2.01,95%CI 1.44–2.80,p<0.001)。
- 将脂蛋白(a)加入SMART风险评分模型后,C统计量(∆C-statistic 0.018,95%CI 0.011–0.034,p=0.002)、净重分类(6.8%,95%CI 0.5%–10.9%,p=0.040)和综合判别(0.3%,95%CI 0.1%–0.7%,p<0.001)均有轻度但显著的改善。
临床怎么用
- 对经血管造影确诊且经历首次心血管事件的冠心病患者,可考虑检测脂蛋白(a)以辅助评估复发心血管事件风险。
- 脂蛋白(a)可为SMART风险评分提供额外预测信息,但改善幅度轻度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Whether lipoprotein(a) (Lp(a)) is a predictor for recurrent cardiovascular events (RCVEs) in patients with coronary artery disease (CAD) has not been established. This study, hence, aimed to examine the potential impact of Lp(a) on RCVEs in a real-world, large cohort of patients with the first cardiovascular event (CVE). METHODS: In this multicentre, prospective study, 7562 patients with angiography-diagnosed CAD who had experienced a first CVE were consecutively enrolled. Lp(a) concentrations of all subjects were measured at admission and the participants were categorised according to Lp(a) tertiles. All patients were followed-up for the occurrence of RCVEs including cardiovascular death, non-fatal myocardial infarction and stroke. RESULTS: During a mean follow-up of 61.45±19.57 months, 680 (9.0%) RCVEs occurred. The results showed that events group had significantly higher Lp(a) levels than non-events group (20.58 vs 14.95 mg/dL, p<0.001). Kaplan-Meier analysis indicated that Lp(a) tertile 2 (p=0.001) and tertile 3 (p<0.001) groups had significantly lower cumulative event-free survival rates compared with tertile 1 group. Moreover, multivariate Cox regression analysis further revealed that Lp(a) was independently associated with RCVEs risk (HR: 2.01, 95% CI: 1.44 to 2.80, p<0.001). Moreover, adding Lp(a) to the SMART risk score model led to a slight but significant improvement in C-statistic (∆C-statistic: 0.018 (95% CI: 0.011 to 0.034), p=0.002), net reclassification (6.8%, 95% CI: 0.5% to 10.9%, p=0.040) and integrated discrimination (0.3%, 95% CI: 0.1% to 0.7%, p<0.001). CONCLUSIONS: Circulating Lp(a) concentration was indeed a useful predictor for the risk of RCVEs in real-world treated patients with CAD, providing additional information concerning the future clinical application of Lp(a).
引用
- Liu HH, Cao YX, Jin JL, et al. Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. Heart. 2020. PMID: 32381650. doi:10.1136/heartjnl-2020-316586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。